Macquarie Group LTD Apellis Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
A detailed history of Macquarie Group LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 184,931 shares of APLS stock, worth $6.79 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
184,931
Previous 221,654
16.57%
Holding current value
$6.79 Million
Previous $13 Million
45.56%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$602 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$426 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$408 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$360 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$213 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $4.04B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...